Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $13.15 Analyst target: $26.86 Upside: 104.26%
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.